The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results
William R. Fair(University of California System), Victor E. Reuter(Memorial Sloan Kettering Cancer Center), Paul Russo(Memorial Sloan Kettering Cancer Center), Nicholas Stroumbakis(Memorial Sloan Kettering Cancer Center), Michael S. Cookson(University of Oklahoma Health Sciences Center), David Cohen(Memorial Sloan Kettering Cancer Center), Colin B. Begg(Memorial Sloan Kettering Cancer Center), Yu Wang(East China Normal University), Warren D.W. Heston(Cleveland Clinic), Pramod C. Sogani(Memorial Sloan Kettering Cancer Center), Joel Sheinfeld(Memorial Sloan Kettering Cancer Center), Harry W. Herr(Memorial Sloan Kettering Cancer Center), Guido Dalgabni(Memorial Sloan Kettering Cancer Center), Armen Aprikian, Scott M. Soloway(Memorial Sloan Kettering Cancer Center)
Cited by 88
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
The Molecular Taxonomy of Primary Prostate Cancer
|Cell|2015|3.3k
Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update
|The Journal of Urology|2007|1.1k
Racial Differences in the Treatment of Early-Stage Lung Cancer
|New England Journal of Medicine|1999|1k